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Abstract
Background: Evidence suggests that subliminal odorants influence human perception and behavior. It has been
hypothesized that the human sex-steroid derived compound 4,16-androstadien-3-one (androstadienone) functions as a
human chemosignal. The most intensively studied steroid compound, androstadienone is known to be biologically relevant
since it seems to convey information about male mate quality to women. It is unclear if the effects of androstadienone are
menstrual cycle related.
Methodology/Principal Findings: In the first experiment, heterosexual women were exposed to androstadienone or a
control compound and asked to view stimuli such as female faces, male faces and familiar objects while their eye
movements were recorded. In the second experiment the same women were asked to rate the level of stimuli attractiveness
following exposure to the study or control compound. The results indicated that women at high conception risk spent more
time viewing the female than the male faces regardless of the compound administered. Women at a low conception risk
exhibited a preference for female faces only following exposure to androstadienone.
Conclusions/Significance: We contend that a woman’s level of fertility influences her evaluation of potential competitors
(e.g., faces of other women) during times critical for reproduction. Subliminally perceived odorants, such as
androstadienone, might similarly enhance intrasexual competition strategies in women during fertility phases not critical
for conception. These findings offer a substantial contribution to the current debate about the effects that subliminally
perceived body odors might have on behavior.
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Introduction
The matter of subliminally perceived odors immediately calls up
the topic of pheromones. Pheromones are chemical signals first
discovered as sex attractants in animals, that appear to exert a
behavioral or physiological response in animals of the same species
[1]. As these chemicals have been primarily investigated in animals
[2], in which the issue of awareness per se cannot be considered, the
possibility that pheromones are also a human phenomenon and
that they could have an effect on human behavior is currently
being debated [3–9]. Due to the complexity of human behavior,
efforts to measure behavioral modifications following exposure to
putative pheromones have only been tentative [8,10]. Some
authors have, moreover, recently challenged the concept of
pheromones in all species [9]. For all intents and purposes, the
present study has circumvented that dispute and has concentrated
its efforts on investigating if a subliminally perceived odorant can
influence human behavior in view of the hypothesis that olfactory
cues can mediate behavioral responses. Extensively studied with
relation to its effects on mood, behavior and brain function [8],
androstadienone, which is found in human sweat and other
secretions, was the steroid compound investigated in the present
study [11–14].
Although the issue is a highly disputed one [6], androstadie-
none, a member of the family of odorous 16-androstenes, is
considered a putative male human pheromone. Androstadienone
has not, however, always been detected in human secretions [14]
and the gender differences reported may have been due to the
small sample sizes assessed [10]. Although the physiological
concentrations produced by human males and females has not
been fully clarified [15–16], androstadienone has been experi-
mentally administered at concentrations over a million times
higher than levels naturally reported in the human body [17]. The
chemical has been shown to have strong pheromone-like
characteristics in the literature which has reported that androsta-
dienone influences emotional attention, modulating interpersonal
perception [18–20], increases women’s positive and decreases
negative moods in a context-dependent manner, enhances the
feeling of being focused [17–19,21–23], and increases women’s
tolerance to pain [24]. High doses of androstadienone, moreover,
determine measurable changes in endocrine status [25] and
autonomic arousal which appear to be specific to women [10,18–
19,26–31]. In neural terms, there is evidence that the effect of
androstadienone in women goes beyond the olfactory system
determining activation of brain areas associated with attention,
social cognition, and sexual behavior [32–37].
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might have a social function in that it may elicit behavioral
responses in women by modulating mate-choice decisions. This
hypothesis has been recently supported by a study carried out on
speed-dating (ecological) situations. Although depending on the
specific speed-dating situation, men were rated more attractive by
women exposed to androstadienone compared to those exposed to
a control compound [38]. In addition, the fact that women showed
concordant strength of preference for facial masculinity and for the
odor of androstadienone has been interpreted as indirect evidence
that the chemical indexes male mate quality [39]. It is well known
that mate preferences are strongly influenced by morphological
traits [40–41] that might enhance physical attractiveness [42]
probably because they signal mate genetic quality [43]. Interest-
ingly, women near peak fertility time show a higher preference for
visual (and auditory) masculinity and a lower one when their
conception risk is low [44–47]. Consistent with evidence that
androstadienone enhances women’s preference for male faces and
that the preference is naturally more pronounced when they are at
high conception risk, we hypothesize that there is a link between
conception risk and exposure to androstadienone. Does andros-
tadienone’s effect on women’s attraction to men vary depending
on the phase in their menstrual cycle? This is the question we have
attempted to answer here.
Experiment 1
The Effect of Androstadienone on Eye Fixation Towards
Female and Male faces and objects
Eye fixation times on female and male faces and on ordinary
objects by heterosexual women at high conception risk (HCR, i.e.
follicular phase) or low conception risk (LCR, i.e. luteal phase)
times were recorded and measured.
Materials and Methods
Ethics statement. The study’s experimental procedures were
approved by the Institutional Review Board at the University of
Padova and were in accordance with the principles of the
Declaration of Helsinki [48]. All the participants gave written
consent to participate in the research.
Participants. Seated in separate areas to ensure privacy, the
members of the original study cohort of 305 individuals (194
women and 111 men) were asked to fill out a questionnaire
concerning their history of nasal congestion or infections, olfactory
dysfunctions, and use of tobacco products or antidepressants. In
the absence of direct hormone values, the questionnaire posed
questions to the women about: use of hormone therapy, including
oral or intravenous contraceptives during the precedent six
months, the regularity of their menstrual cycle, and the
possibility that they could be pregnant. Although all members of
the original cohort took part in the study, data from the 23 women
using contraceptives, the 36 with irregular menstrual cycle, the 8
who described themselves as homosexual or bisexual, the 2 who
were possibly pregnant and the 15 who had used hormonal
contraceptives during the 6 months before experimentation were
not included in the analyses. Data from 16 participants (7 women
and 9 men) were also excluded for technical reasons. As a result,
the data from a total of 103 women (age: mean 22.661.0 years)
and 102 men (age: mean 2261.2 years) were included in the final
analyses. To demonstrate that the effects of androstadienone are
unique to females, male participants were included in the study for
comparative purposes. Selection criteria were determined on the
bases of the questionnaire administered prior to the experimental
session.
Consistent with other studies in the literature, a cycle-length
standardization formula was calculated to determine each woman’s
phase in her cycle. Although intra- and inter-women menstrual
cyclevariabilityisquitehigh,thisisparticularlytrueforthefollicular
rather than for the luteal phase [49]. We standardized the cycle
length to a 28-day cycle by adjusting the follicular phase of each
woman with respect to the length of her normal menstrual cycle.
This process resulted in an invariant luteal phase which remained
constant at 14 days. If a women was in her luteal phase, that is
during the last 14 days of her cycle, her standardized cycle day was
calculated by subtracting 28 days from the normal length of her
cycle and adding the number counting from the first day of her
cycle.Thus, if a woman had a 31-daycycle and it wasthe 23rdsince
the beginning of her cycle, her standardized cycle day would be
calculated as follows: 28231+23=20. If, instead, a woman was in
her follicular phase, that is during the first 14 days of her cycle, her
standardized cycle day was calculated by dividing her actual cycle
day by the length of her normal cycle minus 14, multiplied by 14. If
it was 10th day of her period and her cycle was normally 34 days
long, then the standardized-cycle-day would be calculated as
follows: [10/(34214)]*14=7. For further details, refer to Garver-
Apgar and colleagues [50].
On the basis of these calculations then, our sample was
composed of 51 women in the HCR (or follicular) phase and 52
women in the LCR (or luteal) phase. Three experimental groups of
participants (26 women HCR phase; 26 women LCR phase; 26
men) and three control groups were composed (25 women HCR
phase; 26 women LCR phase; 26 men). Participants were not
given information concerning they study’s hypotheses or the
identity of the compounds involved before the experiment was
carried out. When debriefed and asked to describe the odor they
had smelled, all the participants reported smelling a clove or spicy
odor and none thought they had smelled odorants connected to
the human body, confirming the implicit nature of the study
results. As the chemical’s odor was masked by clove oil, the risk of
including super smellers [51], specific to the female groups since
women are known to be generally better than men at odor task
performances [52–53], was greatly reduced. A further test –
sniffing a pure androstadienone solution - was also carried out in
order to exclude the presence of participants selectively unable to
smell androstadienone (i.e., specific anosmia to androstadienone).
The results showed that none of the participants included within
the final sample could be considered functionally anosmic to the
experimental compound. Those participants (N=27) resulting
anosmic to androstadienone were excluded from the final analysis
for other reasons.
Compounds. The experimental compound consisted of a
250 mM solution of 4,16-androstadien-3-one (Steraloids Inc.,
Newport, RI; purity $98%) dissolved in propylene glycol (purity
$99%) containing 1% clove oil as an odor mask. The control
compound consisted of 1% clove oil in propylene glycol. Measured
amounts of solutions were pipetted onto pads which was used to
apply the experimental or control compound to the area of the
skin between the mouth and the nose of the participants.
Approximately 2 nmols of androstadienone were applied to the
epidermal surface of each of the participants. The methods and
concentrations utilized were chosen to permit comparisons with
findings already outlined in the literature [17,20,22–23,32,38].
Given that the concentration utilized is much higher than that
usually found in nature [21] and quite near the olfactory threshold,
[51] clove oil was added to mask thee conscious perception of its
scent. The compounds were prepared by an independent chemist
who revealed the code to the other experimenters only after the
statistical analyses were completed.
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photographs representing female (N=12) and male (N=12) faces,
and familiar objects (N=12) (Figure 1). The order of stimuli
presentation was fully randomized between and within subjects.
The items included within each stimulus together with their
position within the array were varied at each trial. The items were
included within a matrix in which it was possible to randomly
locate four stimuli at fixed x, y coordinates: top-left area (180, 50
and 428, 362 pixels), top-right (597, 50 and 846, 362 pixels),
bottom-left (180, 408 and 428, 718 pixels) and bottom-right (597,
408 and 846, 718 pixels). The photographs were standardized at
2486310 pixels maintaining the original proportions using an ad-
hoc software (Paint Shop Pro, The Gimp). The photographs were
of faces depicting ordinary looking persons between 20 and 30 age
without distinctive signs (e.g., beard, piercing, particularly long
hair). For standardization purposes each model was asked to
maintain a neutral expression with his/her mouth closed and to
remove any accessories (jewellery and eyeglasses). The photos of
familiar objects included: a cigarette lighter, a screwdriver, a
computer mouse, a telephone, a mobile telephone, a spoon, a
highlighter, a glove, a light bulb, a pair of eyeglasses, a pair of
scissors, a stapler and a pencil sharpener.
Eye-Tracking Measurement. The Eye Position Detector
System (EPDS; sampling frequency: 40 ms) [54] was utilized to
track eye movements. The EPDS gives two types of responses: a
series of x–y coordinates corresponding to the sequence of points
viewed by the participants on the stimulus and a visual pattern,
i.e., the eye track pattern for each item. The computer screen was
divided into four main areas of interest within which the items
composing the stimulus array were presented. Those areas were
considered the valid viewing points and the times the participants
fixated on those points were registered and summed.
Procedures. After the participants filled out the
questionnaire and signed the informed consent statement, they
were accompanied to the testing room and seated in front of a
computer monitor at a distance of ,70 cm. Left alone in the
testing room, they were monitored from an adjacent area via a
mirror and video monitor. For the ‘eye movement’ task the
participants were asked to view the stimulus for 1800 ms displayed
on the computer monitor during which time eye movements were
Figure 1. An example of eye movement trajectories. Eye movement trajectories following exposure to the control compound or
androstadienone for (A) men, (B) women in the HCR phase and (C) women in the LCR phase.
doi:10.1371/journal.pone.0030645.g001
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(N=36). The experimental session lasted ,60 min (from the time
the participant arrived to the time he/she left). The room
temperature and humidity was kept constant during the testing
sessions.
Data Analysis. A three-way ANOVA with treatment
(androstadienone, control compound) and group (women HCR
phase, women LCR phase, men) as between-subjects factors and
item category (females’ faces, males’ faces and objects) as within-
subject factor was performed on the time spent by participants to
view the different items composing the stimulus. Post hoc pairwise
comparisons were performed using t-tests and Bonferroni’s
corrections were applied. A significance threshold of P,.05 was
set for all statistical tests.
Results
Qualitative Analysis of Eye Movement Trajectories. As
shown in Figure 1a, the eye movement trajectory patterns of the
male participants were not affected by exposure to the
experimental or control compounds. The HCR-phase women
spent more time viewing the female faces with respect to the male
faces or the objects following exposure to both compounds
(Figure 1b). The LCR-phase women showed the same eye
movement trajectory pattern as the men following exposure to
the control compound. When exposed to androstadienone, the
LCR-phase women had a pattern that was similar to that observed
in the HCR-phase women (Figure 1c) showing a marked interest in
females faces with respect to the male faces and the objects
(Figure 1c).
Viewing Time. Differences in viewing the various stimuli
were significant (F2,288=52.39, P,0.0001, g
2=0.83). Time spent
viewing the female faces was longer with respect those spent
viewing the male faces and the objects (1133 ms, 970 ms and
813 ms, respectively; ps,0.05). The comparison between the times
spent viewing the male faces and the objects was also significant
(p,0.05). The differences between groups were significant
(F4,288=25.07, P,0.000, g
2=0.66). Post-hoc contrasts revealed
that all three groups spent more time viewing female faces with
respect to the male faces and the objects (Ps,0.05; see Figure 2).
Time spent viewing the objects was similar across the groups
(Ps.0.05; Figure 2). The HCR-phase women spent more time
viewing female faces than did the LCR-phase women or the men
(Ps,0.05; Figure 2). Analysis of the intergroup differences with
regard to the various stimuli (F4,288=18.64, P,0.001, g
2=0.63)
indicated that when exposed to the control compound, all the
groups spent more time viewing the female faces with respect to
the males faces or the objects (Ps,0.05; Figure 3a). The HCR-
phase women spent more time viewing female faces than did the
other two groups (Ps,0.05; Figure 3a). Time spent viewing the
objects was similar across the groups (Ps.0.05; Figure 3a).
Following exposure to androstadienone, the results were similar
to those found following exposure to the control compound as far
as the HCR-phase women and the men were concerned
(Figure 3b). Exposure to the compound, however, provoked a
change in the LCR-phase women who spent more time viewing
the female faces with respect to the male faces and the objects
(Ps,0.05; Figure 3b). In that group, time spent viewing females
faces after exposure to androstadienone was longer than that spent
following exposure to the control compound (1198 vs. 1068 ms;
p,0.05). All the remaining differences across groups, with regard
to the type of compound used, and the stimuli were not significant
(Ps.0.05; Figure 3a–b).
We had originally hypothesized a link between conception risk
and exposure to androstadienone and specifically that the
chemical influenced women’s attraction for male faces depend-
ing on their menstrual cycle phase. The results presented here
Figure 2. A graphical representation of the groups by item category. Mean viewing time in the three groups of participants with respect to
each category. Bars represent the standard error of means.
doi:10.1371/journal.pone.0030645.g002
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to facial stimuli depending on their menstrual cycle phase, but
that the modulation is connected to female rather than to male
stimuli. Specifically, LCR-phase women exposed to androsta-
dienone spent more time viewing female faces than when they
were exposed to the control compound. This effect, together
with the result that HCR-phase women spent more time viewing
female faces regardless of the compound administered seems to
provide indirect evidence that androstadienone can trigger
intrasexual competition strategies by which members of the
same sex compete for mating access to members of the opposite
sex [55].
Intrasexual competition has recently been investigated by
assessing the influence of fertility on the score women give to
photographs of male and female faces [56]. Specifically,
derogation - any act intended to decrease a rival’s perceived
value - was the competitive strategy that was studied. It was found
that during high fertility periods, competition, and hence
derogation, was stronger and this was confirmed by lower ratings
with regard to female facial attractiveness. Consistent with these
observations, the present results seem to indicate that presumably
because they need to evaluate potential rivals at a time critical to
select a mate, the HCR-phase women tend to pay more attention
to other women than to men regardless of the compound
administered while the LCR-phase women behave this way only
when they are exposed to androstadienone.
Subjective scores of visual stimuli were thus collected to assess
intrasexual competition.
Experiment 2
Investigations indicating that female faces are rated significantly
more attractive than male faces [57,58] suggest that female
attractiveness is of evolutionary importance, and hence, a potential
vehicle for competition. The present experiment assessing
intrasexual competition with regard to attractiveness replicated
that presented by Fisher [56]. Following exposure to the control
compound, or androstadienone, the participants were asked to
rate the facial attractiveness of the female faces utilized in
experiment 1. On the basis of the results obtained in experiment 1,
we expected the HCR-phase women to rate female faces less
attractive with respect to the LCR-phase women following
exposure to both compounds and that the latter group would
rate the female faces less attractive only after exposure to
androstadienone.
Materials and Methods
Participants. All 103 women who took part in experiment 1
also participated in the present study and did so during the same
menstrual phase as when they participated in the previous one.
Care was taken to ascertain that they still met all the recruitment
criteria and that the conditions outlined in the questionnaire were
Figure 3. A graphical representation of the groups by category. Mean viewing time in the three groups of participants with respect to each
category following exposure to the control compound (panel a) and to androstadienone (panel b). Bars represent the standard error of means.
doi:10.1371/journal.pone.0030645.g003
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As in the previous experiment, there were 51 HCR-phase women
(days 6–15) and 52 LCR-phase women (days 0–5 and days 16–28).
The participants were randomly assigned to two experimental
groups exposed to androstadienone (26 women HCR phase; 26
women LCR phase) and two control groups exposed to the control
compound (25 women HCR phase; 26 women LCR phase). As no
effects were detected in male participants in experiment 1, none
were included in the second experiment. For similar reasons the
‘object’ category was also excluded.
Procedures. Participants were asked to rate the facial
attractiveness of each of the female faces used for the ‘eye
movement’ experiment using a Likert-type scale (1=extremely
unattractive to 7=extremely attractive). Each of the faces used in
experiment 1 was presented at the center of a computer screen.
Data Analysis. An ANOVA was used to test for differences
between groups (women HCR phase, women LCR phase) and
compounds (androstadienone, control). Post hoc contrasts using t-
tests and Bonferroni’s corrections were applied. A significance
threshold of P,.05 was set for all statistical tests.
Results
The interaction ‘group by compound’ was found to be
significant (F1,96=27.32, P,0.0001, g
2=0.71). Post-hoc tests
revealed that the HCR-phase women exposed to the control
compound rated females’ faces significantly less attractive with
respect to the LCR-phase women (P,0.05; Figure 4). No
differences were found in the ratings given by the HCR-phase
women following exposure to the two compounds (P.0.05;
Figure 4). The LCR-phase women gave different ratings
depending on the compound administered and rated females
faces less attractive following exposure to androstadienone
(P,0.05). These findings corroborate those obtained in experi-
ment 1 and support the hypothesis that female intrasexual
competition, in particular through competitor derogation, are
affected by subliminal odorants such as androstadienone.
Discussion
The aim of this study was to investigate how androstadienone
affects women’s judgment on facial stimuli during different phases
of their menstrual cycle on. Generally speaking, female faces were
viewed for longer times than were male faces or objects. The
HCR-phase women concentrated greater attention on female
faces than did the LCR-phase women regardless of odorant
exposure. The LCR-phase women spent more time viewing
female faces following androstadienone exposure.
Given the numerous studies that have reported an increased
preference for masculinity during ovulation [45] and following
exposure to androstadienone [38], these results might appear
surprising. We did not, in fact, expect to find differences in the
ratings of and behavioral response to female facial stimuli
depending on the compounds administered and the phase in the
women’s menstrual cycle. Since no studies, with the exception of
Hummer and McClintock’s [20], have examined the link between
conception risk and androstadienone exposure in the arena of
facial processing, the present findings can be seen as a novel
addition to this body of research.
In contrast to previous research on a similar topic, photographs
of real people rather than variations on computer-generated facial
stimuli [39,44–46] were utilized here. The argument has been
made, in fact, that it might not be a reliable assumption to evaluate
preferences during the menstrual cycle using morphed faces -
which might ‘‘translate to actual female choice’’ (pp. 2) [59] - as
unmanipulated photographs might convey them better since they
are closer to real world situations.
Eye movements, instead of self-reported measures [60], were
used as the former are not dependent on explicit processes and can
provide a precise measure of the duration of visual interest [61].
Although previous evidence suggests that androstadienone en-
hances feelings of being focused [17,22], no studies have reported
on its effect on sustained attention [23]. The recently published
work by Hummer and McClintock [20] demonstrated that
androstadienone may be able to increase attention to different
Figure 4. A graphical representation of the ratings of facial attractiveness by the two groups. Mean ratings of facial attractiveness for the
LCR- phase and HCR- phase women following exposure to the control compound or androstadienone. Bars represent the standard error of means.
doi:10.1371/journal.pone.0030645.g004
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train of thought connected to a number of psychological effects
related to androstadienone exposure [21,24], it is plausible that a
chemosensory attention related effect does exist and can be tested
in a biologically relevant framework (e.g. in the context of mate
selection process) but not in laboratory conditions [23]. It has been
shown, in fact, that female response to androstadienone is reflected
in brain areas involved in sustained attention [34].
Although all the female and male facial stimuli used in the
present experiments presented neutral expressions, the results
suggest that those stimuli may have prompted an emotional
response drawing the participants’ attention. But, why did HCR-
phase women spend more time viewing female faces and rating
them as less attractive regardless of the compound administered?
And, on the contrary, why did the LCR-phase women manifest
similar behavior only when exposed to androstadienone? It can be
hypothesized that the effects can be related to derogation, an
intrasexual competition strategy used to decrease a rival’s value
[62]. It appears to be a particularly relevant strategy for women
who find themselves competing for desirable mates who must
provide resources rather than attractiveness [55].
But who can be considered a ‘‘rival’’ in our experimental
model? A number of studies investigating how androstadienone
modulates moods indicated the importance of different contexts.
As an example, Jacob and colleagues [27] noted that women
exposed to androstadienone rated their mood more positively in
the presence of a male rather than a female experimenter. It is
possible then that a female technician, as in our case, could have
triggered the competition. In addition, consistent with Zajonc’s
affective primacy theory [63], it is possible that sensory inputs
(either conscious or subliminally perceived) requiring minimal
cognitive involvement (such as receiving task instructions from a
female experimenter or smelling a masked body odor) might play a
determinant role in human reproductive biology [64].
The fact that both groups of women show this ‘competitive’
pattern following androstadienone exposure seems to confirm the
relevance of the compound. Mazzatenta and colleagues [31]
recently hypothesized that androstadienone could have two-fold
‘‘pheromonal-like’’ characteristics in high-peak fertility women. As
reflected in facial thermal skin fluctuations, androstadienone might
first act as a releaser, triggering a sexual arousal status - which may
have set off competition in our case- and secondly as a modulator
– affecting the eye movement pattern registered. In this respect,
these findings seem to be consistent with those reported in a
previous study which demonstrated female intrasexual competition
in terms of attractiveness [56]. Specifically, during critical times for
reproduction women were found to be more derogatory of female
facial attractiveness compared to infertile phases. Analogous
findings were found in HCR-phase women using the same
methodology. Using a more implicit method, we were able to
ascertain that participants viewed female with respect to male faces
longer and with greater attention. Moreover, in contrast to a
previously published study [65], we provided evidence that the
ratings women participants gave to female attractiveness were
modulated when they were exposed to a biologically relevant
odorant at least during a low fertility phase.
On the basis of our and others’ findings, it would seem that
androstadienone modulates voluntary eye movements by eliciting
a cascade of physiological and psychological events. With a certain
degree of caution, it can also be hypothesized that exposure to
below threshold quantities of the chemical masked by another
odor had an effect on our participants’ endocrine system, as
previously shown [25]. This would be consistent with evidence
that in some situations its exposure can lead to measurable
alterations in the endocrine system which in turn might modulate
sexual strategies [25]. It is unclear why androstadienone does not
provoke cumulative effects in terms of female facial processing in
highly fertile women. It is possible that the effects of androstadie-
none in these women are prevented to avoid non-adaptive
behaviors, such as the degeneration of derogation in manifest
verbal (or physical) aggression towards same-sex rivals [66].
There were some limitations to the present study. First, the fact
that female judgment was confined to the attractiveness of females’
faces could have been extended to evaluate emotional dimensions
such as fear and anger which could reinforce the level of
intrasexual competition. This aspect could be considered in future
experiments in which the emotional content of facial expression is
manipulated. Second, the design did not allow for any examina-
tion of the effects of androstadienone to a specific intrasexual
competition behavior. Given that there are several ways in which
women compete intrasexually (e.g., derogating attractiveness,
derogating other women’s fidelity) further research is required to
determine if the chemical’s effect extends to all or only some
vehicles of competition. Third, we were unable to control for
relationship status. Some investigations on intrasexual strategies
have indicated that tactics for competitor derogation are
influenced by the expected duration of the relationship [67]. It is
possible that the strength of intrasexual competition varies in terms
of the desired relationship duration and feelings of commitments.
Fourth, this line of research might benefit from the use of solutions
in which the concentration of androstadienone used is consistent
with that naturally present in the environment. Fifth, using
different odorous body secretions (e.g. isovaleric acid) as control
compounds might give further insights in separating the specific
effects produced by androstadienone from those provoked by
biologically relevant odors in general. Finally, future studies should
include use of objective measurements (e.g. luteinizing hormone
detection kit) instead of self-reports concerning women’s menstrual
cycle in order to reduce possible hormonal variations influencing
sensory and judgment abilities on topics related to mate choice.
Finally, no hormone testing was carried out. As suggested by
Wyart and colleagues [25], future investigations may be able to
reveal a possible correlation between changes in endocrine state
following exposure to androstadienone and differential behavioral
responses to the compound throughout the menstrual cycle.
In conclusion, our results present a novel contribution
suggesting that women’s level of fertility influences the assessment
of potential competitors, causing them to view the faces of other
women more attentively at times critical for reproduction. On the
basis of these findings, subliminally perceived odorants such as
androstadienone seem to be able to enhance intrasexual
competition strategies in women during fertility phases not critical
for conception.
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